The 13 drugs most likely to be chosen for CMS negotiations, according to the study: Ozempic, Rybelsus and Wegovy (semaglutide): Novo Nordisk's treatment for Type 2 diabetes and weight management.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including American Express Company (AXP), ...